BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15701408)

  • 1. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases.
    El-Mabhouh A; Mercer JR
    Appl Radiat Isot; 2005 Apr; 62(4):541-9. PubMed ID: 15701408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases.
    Torres Martin de Rosales R; Finucane C; Foster J; Mather SJ; Blower PJ
    Bioconjug Chem; 2010 May; 21(5):811-5. PubMed ID: 20387897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
    Uehara T; Jin ZL; Ogawa K; Akizawa H; Hashimoto K; Nakayama M; Arano Y
    Nucl Med Biol; 2007 Jan; 34(1):79-87. PubMed ID: 17210464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
    El-Mabhouh AA; Mercer JR
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1240-8. PubMed ID: 18265977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
    El-Mabhouh A; Angelov C; McEwan A; Jia G; Mercer J
    Cancer Biother Radiopharm; 2004 Oct; 19(5):627-40. PubMed ID: 15650456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
    Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS
    Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies.
    Blower PJ; Lam AS; O'Doherty MJ; Kettle AG; Coakley AJ; Knapp FF
    Eur J Nucl Med; 1998 Jun; 25(6):613-21. PubMed ID: 9618576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
    Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
    Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioimmunodetection of 188Re-labeled anti-carcinoembryonic antigen chimeric antibody in nude mice bearing human colon carcinoma].
    Zhao ZG; Ran YL; Zheng R; Kong J; Chen SZ; Yu L; Yang ZH
    Ai Zheng; 2002 May; 21(5):460-3. PubMed ID: 12452032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
    Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
    J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies.
    Griffiths GL; Goldenberg DM; Knapp FF; Callahan AP; Chang CH; Hansen HJ
    Cancer Res; 1991 Sep; 51(17):4594-602. PubMed ID: 1873804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
    Guo R; Ma Y; Zhang R; Liang S; Shen H; Xu H; Li B
    Nuklearmedizin; 2011; 50(6):234-9. PubMed ID: 21808809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C; Schubiger PA; Schibli R
    Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
    Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.
    Lin WY; Lin CP; Yeh SJ; Hsieh BT; Tsai ZT; Ting G; Yen TC; Wang SJ; Knapp FF; Stabin MG
    Eur J Nucl Med; 1997 Jun; 24(6):590-5. PubMed ID: 9169563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions.
    Arstad E; Hoff P; Skattebøl L; Skretting A; Breistøl K
    J Med Chem; 2003 Jul; 46(14):3021-32. PubMed ID: 12825941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
    Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
    J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigations of directly labeling antibodies with rhenium-188.
    Winnard P; Virzi E; Fogarasi M; Rusckowski M; Hnatowich DJ
    Q J Nucl Med; 1996 Jun; 40(2):151-60. PubMed ID: 8909100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.